Furthermore, recent evidence from CF has demonstrated that CFTR-targeted medications can reduce eosinophils and mucus plugs and reverse exaggerated airway enlargement, suggesting a potential novel therapeutic approach for patients with non-CF bronchiectasis with evidence of underlying CFTR dysfunction (156). Here, CFTR is linked to bronchiectasis.